American Rare Earths advances Halleck Creek pilot plant program

American Rare Earths CEO Mark Wall joined Steve Darling from Proactive to announce rapid progress on the company’s pilot plant program aimed at producing pre-production rare earth concentrate from Halleck Creek ore. As part of this advancement, the company has engaged Jaye T. Pickarts, P.E. to lead the pilot plant process, bringing extensive U.S.-based rare earth and project development expertise to this critical stage. Wall explained that Pickarts is a metallurgical engineer and Registered Professional Engineer with more than four decades of experience in mine development, mineral processing, and environmental compliance. His background includes leadership roles in rare earth demonstration plants and Wyoming-based permitting and operations. In previous positions, including a senior role at engineering firm Knight Piésold, Pickarts oversaw the design, construction, and commissioning of rare earth pilot and demonstration facilities. He has also contributed to multiple technical studies, advancing projects from early scoping through to feasibility. His combined expertise in flowsheet development and plant execution will be instrumental in integrating and de-risking the Halleck Creek pilot circuit. To support the program, American Rare Earths has ordered three key pieces of front-end processing equipment. The company has already received two Induced Roll Magnetic Separators (IRMS) manufactured by Mineral Technologies, headquartered in Starke, Florida. In addition, it has ordered a “GradePro” Reflux Classifier from FLSmidth in Salt Lake City, Utah, which is currently being fabricated on an expedited schedule. The remainder of the circuit will utilize standard, well-established processing equipment, allowing the team to focus on efficiently integrating and optimizing these critical components. The company has also announced it has brought on t Tetra Tech, a U.S. based major consulting and engineering services company, to complete an Oxides to Metals study for the Company’s heavy rare earths stream. The study will evaluate options to convert separated heavy rare earth oxides from the American Rare Earths Halleck Creek Project in Wyoming all the way to metal, a critical midstream step immediately preceding the manufacture of permanent magnets relied upon by defense and advanced technology sectors. #proactiveinvestors #americanrareearthslimited #asx #arr #otcqx #arrnf #adr #amrry #wyomingrareinc #RareEarths #HalleckCreek #PilotPlant #MineralProcessing #CriticalMinerals #Metallurgy #MiningInnovation #TREO #ResourceDevelopment #WyomingMining #ProcessEngineering #CleanTech #SupplyChain #ProjectDevelopment

Valereum PLC (AQSE:VLRM, FRA:6TJ, OTCQB:VLRMF) CEO Gary Cottle talked with Proactive about the launch of VGOLD, a new product aiming to differentiate itself in the growing tokenised gold market by offering yield alongside digital gold exposure. Cottle explained that VGOLD stands out as “probably the only gold token that will pay a yield or a coupon,” adding that investors who stake tokens for longer than a year could see returns between 10% and 15%. This positions VGOLD as both a store of value and an income-generating digital asset. The discussion also covered liquidity and flexibility. Cottle noted that VGOLD and its associated VGOLD-CORE tokens are designed to be “very liquid,” with the ability to convert into cash, tether gold, and other assets. This flexibility allows Valereum to actively manage and deploy capital while maintaining exposure to gold-linked instruments. Part of the strategy includes transitioning existing bond assets into VGOLD-CORE, described as a liquidity pool, subject to verification processes for underlying assets. The company expects this to enhance both returns and usability. Cottle also highlighted the importance of Valereum’s collaboration with Quorium Global Photonics (QGP), describing the partnership as fundamental to building the VGOLD ecosystem. The alignment includes shared technology, revenue opportunities, and complementary asset pipelines. Looking ahead, a potential US listing remains a key objective, though dependent on achieving stable revenues. With multiple deals in progress across gold and real estate tokenisation, VGOLD is seen as a primary driver toward near-term revenue generation. For more insights like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #Valereum #VGOLD #TokenizedGold #GoldInvestment #CryptoAssets #DigitalGold #BlockchainFinance #YieldInvesting #Fintech #RealWorldAssets #RWA #CryptoNews #Investing #GoldTokens #Web3Finance

Abingdon Health PLC (AIM:ABDX) executive chairman Dr Chris Hand talked with Proactive's Stephen Gunnion about the company’s strong first-half performance, recent contract wins and growth outlook in the diagnostics market. Hand explained that Abingdon Health operates as a contract development and manufacturing organisation specialising in lateral flow and rapid diagnostic testing, now offering a full-service, end-to-end solution from product development through to regulatory approval and manufacturing. This expanded “one-stop shop” model is helping differentiate the company in a competitive sector. The company reported a 45% increase in revenue in the first half, with expectations for an even stronger second half. Hand also highlighted two major contract wins, including a $2.5 million international project and a £4.8 million agreement to develop multiplex lateral flow tests. These tests allow multiple biomarkers to be analysed in a single device, moving beyond traditional yes/no diagnostics. As Hand noted, “these tests [are] basically an onsite version of a lab test,” reflecting growing demand from biotech and pharmaceutical customers. The company is also expanding its US presence, with its Madison, Wisconsin, facility supporting increased manufacturing capacity and trading of its shares on the OTCQB to improve investor access and liquidity. Looking ahead, continued contract momentum and revenue growth are expected to drive performance through the second half of the year. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #AbingdonHealth #Diagnostics #LateralFlow #Biotech #HealthcareInnovation #RapidTesting #MedTech #Pharma #InvestorNews #SmallCaps #AIMMarket #USExpansion #MultiplexTesting #GrowthStocks

RC Fornax PLC (AIM:RCFX) finance director Rob Shepherd talked with Proactive's Stephen Gunnion about the company’s latest trading update, highlighting strong sales momentum, growing order visibility, and a positive outlook driven by both internal improvements and favourable market conditions. Shepherd explained that the company has already surpassed its previous full-year revenue within just seven months, supported by over £5.1 million in sales visibility. This performance reflects improving operational execution and a more structured commercial approach following internal changes. He noted that “we're already in excess of what we did for the previous 12 months,” underlining the pace of growth. A key theme was the importance of recurring revenue. While contracts are typically shorter-term, RC Fornax has seen sustained relationships with clients over multiple years, demonstrating consistent value delivery. Shepherd emphasised that repeat business shows “customers like what we do,” reinforcing confidence in the company’s model. The discussion also touched on external drivers, particularly increased global defence spending amid geopolitical tensions. Within a UK defence budget of around £64–65 billion, RC Fornax estimates an addressable opportunity of approximately £1.5 billion. Despite currently holding a small share of that market, Shepherd highlighted significant growth potential. Operational improvements, including new leadership and sales processes, are also contributing to stronger commercial performance and new client wins. For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future updates. #RCFornax #DefenceSector #TradingUpdate #UKStocks #SmallCapStocks #GrowthStocks #DefenceSpending #InvestorUpdate #MarketOutlook #RevenueGrowth

Ariana Resources PLC (AIM:AAU, ASX:AA2, FRA:4A6) managing director Kerim Sener talked with Proactive's Stephen Gunnion about the company’s 2025 results, funding position, and progress across its key gold projects, including Dokwe and Tavşan. Sener outlined a “very pleasing end to the year,” highlighting a stronger cash position following an investment from Xinhai, leaving the company with approximately £5.4 million in cash. He explained that Ariana is now “adequately provided for through the duration of the coming year and the feasibility study on Dokwe,” positioning the company to advance one of its most important growth assets. The discussion also addressed the reported shift from profit to loss, which Sener clarified was “a paper treatment only,” driven by a non-cash accounting adjustment related to the valuation of its investment in Zenit. Operationally, the Dokwe project continues to deliver encouraging exploration results. Sener pointed to strong drilling intercepts, including “4m at about 17g per ton of gold,” which demonstrate newly identified extensions of mineralisation and support the potential for a future resource upgrade. Further drilling and metallurgical work are planned in the coming months. Meanwhile, the Tavşan mine has entered production and is expected to begin contributing dividend flow during the year, supporting Ariana Resources PLC’s broader growth strategy. Sener also emphasised that the company is “very well funded through the course of this year,” with additional financial and technical backing from Xinhai helping to advance feasibility work. For more videos like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss an update. #ArianaResources #GoldExploration #MiningStocks #DokweProject #GoldDrilling #TavsanMine #ASX #LSE #MiningNews #ResourceInvesting #GoldMining #ExplorationUpdate #SmallCapStocks #InvestorNews

Quantum Blockchain Technologies PLC (AIM:QBT, FRA:BYA1) CEO Francesco Gardin talked with Proactive's Stephen Gunnion about latest developments across the company’s US patent application process, AI software implementation, and ongoing hardware deployment. Gardin provided an update on the ASIC Ultraboost patent application in the United States, explaining that the company is actively engaging with examiners to move the process forward. He noted that QBT is working closely with its patent attorney to secure progress, with a call scheduled to accelerate feedback. Gardin said the company believes strongly in the innovation behind the technology, stating: “We definitely think that this is an invention which is innovative and we will work very hard to get it to be granted.” He added that a potential compromise could involve narrowing the scope of claims to reach approval. On the operational side, Gardin discussed the AI software Oracle implementation underway at the company’s Milan-based lab. He highlighted that the ASIC manufacturer has provided extensive technical support, enabling smoother integration. The Mining Development Kit (MDK) has now been shipped to Oregon for testing, with delivery to Milan expected shortly after Easter. This step is seen as key to advancing system validation and deployment. Additionally, Gardin addressed preparations for the upcoming bondholders meeting, outlining ongoing efforts to reduce bond exposure through conversion and continued negotiations. For more insights and updates, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications for future content. #QuantumBlockchain #FrancescoGardin #CryptoMining #BlockchainTechnology #ASIC #ArtificialIntelligence #PatentUpdate #BitcoinMining #QBT #TechInnovation #MiningRig #AIsoftware #InvestingNews #ProactiveInvestors

Purepoint Uranium Group CEO Chris Frostad joined Steve Darling from Proactive to discuss the company’s latest uranium exploration progress at its Dorado project in northern Saskatchewan, as well as the broader process of making and advancing a discovery. Frostad explained that Purepoint Uranium Group operates in one of the world’s most prolific uranium regions, collaborating with major partners including Cameco, Orano, and ISOEnergy. The discussion focused on the company’s recent discovery at the Dorado project, particularly within the Nova zone, where initial drilling intersected high-grade uranium mineralization. Highlighting that discovery is only the first step, Frostad noted: “The real work happens after the fact,” emphasizing the importance of follow-up drilling to confirm whether mineralization is repeatable and to better understand the structure and controls of the deposit. The company is now conducting additional drilling to expand on the initial findings and determine the direction and continuity of the uranium system. Frostad also outlined how modern exploration relies heavily on geophysics and geological modelling. He explained that uranium itself is not directly detectable through geophysical surveys; instead, the company analyzes surrounding rock types, structures, and alteration patterns to guide drilling decisions and refine its exploration model. With ongoing work at Dorado, Purepoint Uranium Group aims to define the scale and orientation of the mineralized system and determine the next steps for continued exploration. #proactiveinvestors #purepointuraniumgroup #tsxv #ptu #otcqb #ptuuf #UraniumExploration #DoradoProject #NorthernSaskatchewan #HighGradeUranium #MiningDiscovery #Geophysics #MineralExploration #Cameco #Orano #ISOEnergy #ResourceDevelopment #SustainableEnergy #NuclearFuel #ExplorationUpdate

American Resources Corp CFO Kirk Taylor joined Steve Darling from Proactive to announce a strategic collaboration with Mitsubishi Materials Corporation, a global leader in advanced materials and resource circulation. The partnership includes a strategic investment in ReElement Technologies, reinforcing confidence in its refining-first platform and its role in strengthening critical mineral supply chains. Taylor explained that the collaboration is designed to accelerate the development of scalable and economically viable refining solutions across the United States and allied nations. In the U.S., the partnership will focus on supporting ReElement’s refining operations through feedstock sourcing, tolling arrangements, and offtake opportunities—key components in expanding domestic refining capacity. In Japan, the companies will jointly explore opportunities to commercialize rare earth and critical mineral recycling solutions. This effort will combine MMC’s well-established recycling infrastructure with ReElement’s proprietary chromatographic refining platform, creating a powerful synergy aimed at improving efficiency and sustainability in the sector. ReElement’s refining-first approach is built for flexibility, allowing it to process both recycled and primary feedstocks into high-purity materials. This capability positions the company as a scalable solution to the global midstream refining gap, a critical bottleneck in the supply chain for rare earth elements and other essential minerals. Unlike conventional solvent-based refining methods—which are often difficult to implement outside of China due to environmental, capital, and operational challenges—ReElement’s platform offers a modular, cost-effective, and environmentally responsible alternative. He also անդրscored the importance of samarium, a critical element used in defence-related magnet applications, emphasizing the company’s role in supporting secure and resilient supply chains for the US and allied nations. Taylor noted that American Resources Corp has built a flexible mineral refinement platform capable of adapting to evolving customer needs and addressing new challenges across the sector. #proactiveinvestors #americanresourcescorporation #nasdaq #arec #SustainableMining, #MineralRefining, #RecyclingInnovation, #CriticalMinerals, #ReElement #MitsubishiMaterials #CriticalMinerals #RareEarths #SupplyChain #EnergyTransition #AdvancedMaterials #RecyclingInnovation #MiningTech #SustainableSolutions #USManufacturing #JapanInnovation #ResourceSecurity #CleanTech

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company’s Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao’s independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma’s continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a rigorous framework to isolate the incremental benefit of the drug component while also assessing both visual (clinical) and histological clearance endpoints. Dr. Rao emphasized that the trial design enables a clear understanding of treatment effectiveness, combining real-world clinical observations with detailed pathological analysis. He noted that the findings carry important implications for patient care, particularly in reducing reliance on invasive procedures. One of the most compelling outcomes highlighted was that approximately three out of four treated lesions achieved visual tumor clearance. This suggests that a significant number of patients could potentially avoid immediate surgical intervention, offering a less invasive treatment alternative for certain forms of skin cancer. Dr. Rao, a dermatologist, dermatopathologist, Mohs surgeon, and clinical investigator, brings extensive expertise in skin oncology. He serves as Professor of Dermatology and Pathology and Director of Clinical Research at Rutgers Robert Wood Johnson Medical School, with additional academic roles at Weill Cornell Medical College and California Health Sciences University. The independent validation strengthens Medicus Pharma’s position as it continues to develop SkinJect as a novel, minimally invasive treatment option, with the potential to reshape how certain skin cancers are managed in clinical practice #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Dermatology #SkinCancer #BasalCellCarcinoma #OncologyInnovation #Biotech #DrugDelivery #Microneedle #Doxorubicin #ClinicalResearch #HealthcareInnovation #MedicalBreakthrough #ProactiveInvestors

Miivo Holdings CEO Alex Damouni joined Steve Darling from Proactive to share news to highlight the company’s AI-powered platform designed to help small and medium-sized businesses identify early warning signs and improve operational performance. Damouni explained that Miivo brings together financial, operational, and customer data into a single, unified platform, giving business owners a real-time, consolidated view of their company. By leveraging artificial intelligence, the system identifies potential issues early and delivers prioritized, tailored recommendations. “What Miivo is, it's an AI-powered platform that detects these early warning problems about your business by pulling information from different sources,” he said. The platform is built to serve two core segments: businesses facing financial or operational challenges, and more established companies seeking to streamline workflows, automate manual processes, and scale more efficiently. Damouni emphasized that Miivo’s flexible approach is designed to “meet you where you are,” offering both self-service tools and more comprehensive managed solutions. To expand accessibility, the company recently launched its Miivo Starter plan, enabling smaller businesses to adopt the platform independently at a lower cost entry point. At the same time, Miivo continues to offer customized, hands-on support for clients requiring deeper integration and guidance. Looking ahead, Miivo is executing a dual growth strategy that includes developing additional self-service offerings and pursuing a strategic acquisition to broaden its geographic reach and increase recurring revenue. The platform is already gaining traction globally, with users across North America, Europe, the Middle East, and India. With its focus on AI-driven insights, automation, and data integration, Miivo is positioning itself as a powerful tool for businesses aiming to proactively manage risk, enhance decision-making, and drive sustainable growth. #proactiveinvestors #miivoholdings #tsxv #mivo #AIForBusiness #BusinessIntelligence #SMBTech #OperationalExcellence #DataDriven #AIAutomation #EarlyWarningSystem #FinancialInsights #WorkflowOptimization #BusinessGrowth #TechInnovation #GlobalExpansion #RiskManagement #SaaSPlatform